2 Information about atezolizumab

Marketing authorisation indication

2.1 Atezolizumab (Tecentriq, Roche) has a marketing authorisation for the 'first-line treatment of adult patients with metastatic non-small-cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or at least 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC'.

Dosage in the marketing authorisation

2.2 The dosage schedule will be available in the summary of product characteristics.

Price

2.3 The list price of atezolizumab is £3,807.69 per 20-ml vial (for the 1,200 mg dose; excluding VAT; BNF online accessed March 2021).

The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.